The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus

References

• Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 342(8867), 341–344 (1993).
   PubMed Web of Science ®Google Scholar
• Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J. Rheumatol. 13(3), 486–489 (1986).
   PubMed Web of Science ®Google Scholar
• Asherson RA, Khamashta MA, Ordi-Ros J et al. The ‘primary’ antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68(6), 366–374 (1989).
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 68(6), 353–365 (1989).
   PubMed Web of Science ®Google Scholar
• Triplett DA. Antiphospholipid antibodies. Arch. Pathol. Lab. Med. 126(11), 1424–1429 (2002).
   PubMed Web of Science ®Google Scholar
• Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis; type, incidence, and cause. J. Am. Med. Assoc. 150(5), 467–473 (1952).
   PubMed Web of Science ®Google Scholar
• Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog. Hemost. Thromb. 1, 75–95 (1972).
   PubMedGoogle Scholar
• Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2(8361), 1211–1214 (1983).
   PubMed Web of Science ®Google Scholar
• Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford) doi:10.1093/rheumatology/ket126 (2013).
   PubMedGoogle Scholar
• Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21(5), 275–286 (1992).
   PubMed Web of Science ®Google Scholar
• Vianna JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, Hughes GR. Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann. Rheum. Dis. 51(2), 160–161 (1992).
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40(9), 1725 (1997).
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46(4), 1019–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 376(9751), 1498–1509 (2010).
   PubMed Web of Science ®Google Scholar
• Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr. Opin. Hematol. 18(5), 343–348 (2011).
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J. Rheumatol. 16(4), 482–488 (1989).
   PubMed Web of Science ®Google Scholar
• Rai RS, Regan L, Clifford K et al. Antiphospholipid antibodies and β 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum. Reprod. 10(8), 2001–2005 (1995).
   PubMed Web of Science ®Google Scholar
• Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr. Rheumatol. Rep. 9(3), 219–225 (2007).
   PubMedGoogle Scholar
• Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke. 31(12), 3067–3078 (2000).
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 368(11), 1033–1044 (2013).
   PubMed Web of Science ®Google Scholar
• Charakida M, Besler C, Batuca JR et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 302(11), 1210–1217 (2009).
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Zhang JY, Qi M et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen ß2-glycoprotein I. Arthritis Rheum. 63(9), 2774–2782 (2011).
   PubMed Web of Science ®Google Scholar
• Agar C, van Os GM, Mörgelin M et al. β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116(8), 1336–1343 (2010).
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 8(11), 998–1005 (2009).
   PubMed Web of Science ®Google Scholar
• Ames PR, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J. Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome. J. Rheumatol. 37(12), 2523–2530 (2010).
   PubMed Web of Science ®Google Scholar
• Ramesh S, Morrell CN, Tarango C et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via ß2GPI and apoER2. J. Clin. Invest. 121(1), 120–131 (2011).
   PubMed Web of Science ®Google Scholar
• Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 52(5), 1545–1554 (2005).
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Gao L, Qi M et al. Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J. Autoimmun. 39(3), 121–129 (2012).
   PubMed Web of Science ®Google Scholar
• de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109(4), 1490–1494 (2007).
   PubMed Web of Science ®Google Scholar
• Roldan V, Lecumberri R, Muñoz-Torrero JF et al.; RIETE Investigators. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb. Res. 124(2), 174–177 (2009).
   PubMed Web of Science ®Google Scholar
• Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am. J. Med. 96(1), 3–9 (1994).
   PubMed Web of Science ®Google Scholar
• Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr. Rheumatol. Rep. 13(1), 59–69 (2011).
   PubMed Web of Science ®Google Scholar
• Pengo V. APS – controversies in diagnosis and management, critical overview of current guidelines. Thromb. Res. 127(Suppl. 3), S51–S52 (2011).
   PubMedGoogle Scholar
• Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13(1), 77–80 (2011).
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20(2), 206–218 (2011).
   PubMed Web of Science ®Google Scholar
• Wijetilleka S, Scoble T, Khamashta M. Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Curr. Opin. Rheumatol. 24(5), 473–481 (2012).
   PubMed Web of Science ®Google Scholar
• Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42(7), 1309–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann. Rheum. Dis. 71(2), 242–244 (2012).
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Amengual O, Atsumi T et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 20(2), 191–205 (2011).
   PubMed Web of Science ®Google Scholar
• Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am. J. Clin. Pathol. 94(4), 476–484 (1990).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 74(4), 1185–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 43(2), 440–443 (2000).
   PubMed Web of Science ®Google Scholar
• Weber M, Hayem G, Meyer O. The Sapporo criteria for antiphospholipid syndrome: comment on the article by Lockshin et al. Arthritis Rheum. 44(8), 1965–1966 (2001).
   PubMed Web of Science ®Google Scholar
• Bobba RS, Johnson SR, Davis AM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised Sapporo criteria add value? J. Rheumatol. 34(7), 1522–1527 (2007).
   PubMed Web of Science ®Google Scholar
• Pengo V. Antiphospholipid syndrome: interpretation of laboratory data. J. Thromb. Haemost. 9(2), 402–403 (2011).
   PubMedGoogle Scholar
• Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 66(7), 927–930 (2007).
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93(6), 1147–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68(2), 238–241 (2009).
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61(1), 29–36 (2009).
   PubMed Web of Science ®Google Scholar
• Yang P, Kruh JN, Foster CS. Antiphospholipid antibody syndrome. Curr. Opin. Ophthalmol. 23(6), 528–532 (2012).
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-Glycoprotein I activity. Thromb. Res. 120(1), 127–133 (2007).
   PubMed Web of Science ®Google Scholar
• Reber G, Arvieux J, Comby E et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d’Etudes sur l’Hémostase et la Thrombose). Thromb. Haemost. 73(3), 444–452 (1995).
   PubMed Web of Science ®Google Scholar
• Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin. Diagn. Lab. Immunol. 6(6), 775–782 (1999).
   PubMedGoogle Scholar
• Rampazzo P, Biasiolo A, Garin J et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb. Haemost. 85(1), 57–62 (2001).
   PubMed Web of Science ®Google Scholar
• Wisløff F, Jacobsen EM, Liestøl S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb. Res. 108(5–6), 263–271 (2002).
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5), 1827–1832 (2003).
   PubMed Web of Science ®Google Scholar
• de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J. Thromb. Haemost. 3(9), 1993–1997 (2005).
   PubMed Web of Science ®Google Scholar
• de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104(12), 3598–3602 (2004).
   PubMed Web of Science ®Google Scholar
• Pengo V, Banzato A, Denas G et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun. Rev. 12(8), 832–834 (2012).
   PubMed Web of Science ®Google Scholar
• Moffat K, Raby A, Crowther M. Lupus anticoagulant testing. Methods Mol. Biol. 992, 97–108 (2013).
   PubMedGoogle Scholar
• De Laat B, Derksen RH, Reber G et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-β2-glycoprotein autoantibodies. J. Thromb. Haemost. 9(1), 149–153 (2011).
   PubMedGoogle Scholar
• de Laat B, Pengo V, Pabinger I et al. The association between circulating antibodies against domain I of β2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 7(11), 1767–1773 (2009).
   PubMed Web of Science ®Google Scholar
• Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann. Rheum. Dis. 62(12), 1127 (2003).
   PubMed Web of Science ®Google Scholar
• Lazurova I, Macejova Z, Tomkova Z et al. Severe limb necrosis: primary thrombotic microangiopathy or ‘seronegative’ catastrophic antiphospholipid syndrome? A diagnostic dilemma. Clin. Rheumatol. 26(10), 1737–1740 (2007).
   PubMed Web of Science ®Google Scholar
• Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin. Thromb. Hemost. 34(4), 340–346 (2008).
   PubMed Web of Science ®Google Scholar
• Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called ‘seronegative antiphospholipid syndrome’. Autoimmun. Rev. 9(2), 90–92 (2009).
   PubMed Web of Science ®Google Scholar
• Mcintyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J. Autoimmun. 15(2), 185–193 (2000).
   PubMed Web of Science ®Google Scholar
• Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry 38(12), 3591–3598 (1999).
   PubMed Web of Science ®Google Scholar
• Tsuda T, Yoshimura H, Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X–prothrombin system. Blood Coagul. Fibrinolysis 17(6), 465–469 (2006).
   PubMed Web of Science ®Google Scholar
• Baumgärtner P, Geiger M, Zieseniss S et al. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J. Cell Biol. 179(4), 793–804 (2007).
   PubMed Web of Science ®Google Scholar
• Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb. Haemost. 80(6), 936–941 (1998).
   PubMed Web of Science ®Google Scholar
• Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J. Rheumatol. 23(8), 1369–1374 (1996).
   PubMed Web of Science ®Google Scholar
• Sugi T, Katsunuma J, Izumi S, McIntyre JA, Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil. Steril. 71(6), 1060–1065 (1999).
   PubMed Web of Science ®Google Scholar
• Gris JC, Quéré I, Sanmarco M et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study – NOHA. Thromb. Haemost. 84(2), 228–236 (2000).
   PubMed Web of Science ®Google Scholar
• Sanmarco M, Alessi MC, Harle JR et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb. Haemost. 85(5), 800–805 (2001).
   PubMed Web of Science ®Google Scholar
• Sugi T, Matsubayashi H, Inomo A, Dan L, Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J. Obstet. Gynaecol. Res. 30(4), 326–332 (2004).
   PubMed Web of Science ®Google Scholar
• Sanmarco M, Gayet S, Alessi MC et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb. Haemost. 97(6), 949–954 (2007).
   PubMed Web of Science ®Google Scholar
• Hirmerova J, Ulcova-Gallova Z, Seidlerova J et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin. Appl. Thromb. Hemost. 16(3), 318–325 (2010).
   PubMed Web of Science ®Google Scholar
• Staub HL, Harris EN, Khamashta MA, Savidge G, Chahade WH, Hughes GR. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann. Rheum. Dis. 48(2), 166–169 (1989).
   PubMed Web of Science ®Google Scholar
• Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun. Rev. 12(2), 230–234 (2012).
   PubMed Web of Science ®Google Scholar
• Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil. Steril. 66(4), 540–546 (1996).
   PubMed Web of Science ®Google Scholar
• Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol. Reprod. 56(1), 50–58 (1997).
   PubMedGoogle Scholar
• Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet. Gynecol. 101(3), 455–462 (2003).
   PubMed Web of Science ®Google Scholar
• Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum. Reprod. 17(11), 2981–2985 (2002).
   PubMed Web of Science ®Google Scholar
• Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun. Rev. 10(10), 609–616 (2011).
   PubMed Web of Science ®Google Scholar
• Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb. Haemost. 76(6), 916–924 (1996).
   PubMed Web of Science ®Google Scholar
• Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb. Haemost. 77(3), 486–491 (1997).
   PubMed Web of Science ®Google Scholar
• Donohoe S, MacKie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br. J. Haematol. 113(2), 544–549 (2001).
   PubMed Web of Science ®Google Scholar
• Tincani A, Morozzi G, Afeltra A et al.; Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin. Exp. Rheumatol. 25(2), 268–274 (2007).
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Ghirardello A, Zampieri S et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J. Thromb. Haemost. 5(6), 1158–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb. Haemost. 93(2), 289–297 (2005).
   PubMed Web of Science ®Google Scholar
• Atsumi T, Ieko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 43(9), 1982–1993 (2000).
   PubMed Web of Science ®Google Scholar
• Atsumi T, Koike T. Antiprothrombin antibody: why do we need more assays? Lupus 19(4), 436–439 (2010).
   PubMed Web of Science ®Google Scholar
• Frank M, Sodin-Semrl S, Irman S, Bozic B, Rozman B. β2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. Autoimmun. Rev. 9(1), 5–10 (2009).
   PubMed Web of Science ®Google Scholar
• Galli M. Non β 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 5(5), 388–392 (1996).
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Quinn AS, Taatjes DJ. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 17(10), 922–930 (2008).
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Lapinski R et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 104(9), 2783–2790 (2004).
   PubMed Web of Science ®Google Scholar
• Nojima J, Kuratsune H, Suehisa E et al. Association between the prevalence of antibodies to β(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin. Chem. 47(6), 1008–1015 (2001).
   PubMed Web of Science ®Google Scholar
• Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H. Anti-β 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage. Br. J. Haematol. 113(4), 911–914 (2001).
   PubMed Web of Science ®Google Scholar
• de Laat B, Derksen RH, Mackie IJ et al. Annexin A5 polymorphism (-1C–>T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann. Rheum. Dis. 65(11), 1468–1472 (2006).
   PubMed Web of Science ®Google Scholar
• Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J. Thromb. Haemost. 10(12), 2512–2518 (2012).
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 8(2), 237–242 (2010).
   PubMed Web of Science ®Google Scholar
• Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann. Rheum. Dis. 70(8), 1517–1518 (2011).
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118(17), 4714–4718 (2011).
   PubMed Web of Science ®Google Scholar